ZACKSยท2025-06-18 14:35Core Insights - Eli Lilly (LLY) announced the acquisition of Verve Therapeutics (VERV), focusing on gene therapies for cardiovascular diseases, particularly VERVE-102, which aims to reduce cholesterol levels [1][9] - The acquisition has positively impacted the share prices of other gene-editing companies, including Crispr Therapeutics (CRSP) and Intellia Therapeutics (NTLA), while Editas Medicine (EDIT) saw a decline [2][9] Gene-Editing Companies Overview - The field of gene editing is rapidly evolving, with companies utilizing CRISPR/Cas9 technology to treat genetic diseases by correcting DNA defects [3] - Intellia Therapeutics (NTLA) focuses on CRISPR-based therapies, with its lead candidates targeting ATTR amyloidosis and hereditary angioedema, and saw a 6.9% increase in share price [4] - Crispr Therapeutics (CRSP) is developing therapies for various diseases and achieved a milestone with the approval of its CRISPR/Cas9 therapy, Casgevy, in November 2023, resulting in a 3.9% share price increase [5] - Beam Therapeutics (BEAM) is advancing base editing programs, including BEAM-101 for sickle cell disease, which received orphan drug designation from the FDA [6] - Editas Medicine is developing treatments using its proprietary CRISPR technology, focusing on in vivo pipeline development [7] Mergers and Acquisitions Activity - Mergers and acquisitions (M&A) in the pharma/biotech sector have increased significantly in 2025, indicating a focus on portfolio expansion and innovation [8][12] - Notable acquisitions include Sanofi's planned acquisition of Blueprint Medicines for up to $9.5 billion and Johnson & Johnson's acquisition of Intra-Cellular Therapies for approximately $14.6 billion [10][11]